報價延遲最少15分鐘:2025/07/15 09:53 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.875 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.61/-4.42
|
|
企業價值
2.28B
|
| 資產負債 |
|
每股賬面淨值
11.17
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
63.52M
|
|
每股收益
0.81
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/15 09:53 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States. |
